Research programme: salmonella vaccine - Syntiron

Drug Profile

Research programme: salmonella vaccine - Syntiron

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Syntiron LLC
  • Developer Epitopix
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Salmonella infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Salmonella-infections in USA
  • 12 Nov 2010 Syntiron receives a Qualifying Therapeutic Discovery Project grant for its bacterial vaccine development programme
  • 20 Oct 2006 Preclinical trials in Salmonella infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top